KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 170 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $364 | -100.0% | 272 | -100.0% | 0.00% | -100.0% |
| Q4 2022 | $6,771,484 | +35539.4% | 1,991,613 | +56803.2% | 0.02% | – |
| Q3 2022 | $19,000 | -99.6% | 3,500 | -99.0% | 0.00% | -100.0% |
| Q3 2020 | $5,106,000 | -67.2% | 349,723 | -86.5% | 0.03% | -67.9% |
| Q2 2019 | $15,552,000 | +7.7% | 2,596,323 | +68.4% | 0.08% | +14.1% |
| Q4 2018 | $14,446,000 | -10.8% | 1,541,718 | +62.2% | 0.07% | +6.0% |
| Q3 2018 | $16,187,000 | -33.9% | 950,493 | -34.1% | 0.07% | -31.6% |
| Q2 2018 | $24,503,000 | -6.8% | 1,442,183 | -26.4% | 0.10% | -10.9% |
| Q1 2018 | $26,283,000 | -18.3% | 1,958,527 | -41.6% | 0.11% | -20.9% |
| Q4 2017 | $32,179,000 | +2236.9% | 3,351,996 | +8407.6% | 0.14% | +1290.0% |
| Q3 2014 | $1,377,000 | +270.2% | 39,400 | +392.5% | 0.01% | +400.0% |
| Q2 2014 | $372,000 | – | 8,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 3,561,052 | $26,245,000 | 5.86% |
| Palo Alto Investors LP | 5,621,533 | $41,431,000 | 3.20% |
| Iron Triangle Partners LP | 2,000,000 | $14,740,000 | 1.75% |
| Altium Capital Management LP | 645,000 | $4,754,000 | 1.59% |
| Birchview Capital, LP | 269,332 | $1,985,000 | 1.43% |
| Rubric Capital Management LP | 3,607,443 | $26,587,000 | 0.96% |
| Lombard Odier Asset Management (Switzerland) SA | 776,053 | $5,720,000 | 0.45% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,344,929 | $9,912,000 | 0.40% |
| Golden State Equity Partners | 41,850 | $308,000 | 0.16% |
| Hennion & Walsh Asset Management, Inc. | 385,837 | $2,844,000 | 0.15% |